Physician profile
John Robert Hollerud
NPI 1942317888
$539.68
in general payments reported to CMS, 2019-2025
16 companies · $108 in 2025
The $108 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.03 · 2020: $54.52 · 2021: $61.27 · 2022: $106 · 2023: $93.69 · 2024: $89.31 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $76.30 | 2023-2025 | Immunocap |
| Pfizer INC. | $74.26 | 2020-2024 | |
| Sanofi Pasteur INC. | $64.41 | 2022-2024 | |
| Cranial Technologies, INC | $44.17 | 2025 | Doc Band |
| Ultragenyx Pharmaceutical INC. | $39.80 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.27 | 2021 | |
| Corium, LLC | $35.96 | 2022-2023 | Azstarys |
| Kaleo, INC. | $30.99 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $28.70 | 2020 | |
| Sanofi-Aventis U.S. LLC | $21.28 | 2024 | |
| Seqirus USA INC | $18.52 | 2024 | Flucelvax |
| Collegium Pharmaceutical, INC. | $17.30 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $14.67 | 2025 | Ycanth |
| Tris Pharma INC | $13.29 | 2020 | |
| Merck Sharp & Dohme LLC | $12.04 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $11.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hollerud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.